A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109

NCT01624532 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Anthrax

Interventions

BIOLOGICAL: GC1109 or Placebo of GC1109

Sponsor

Green Cross Corporation

Collaborators

[object Object]